323 related articles for article (PubMed ID: 16401734)
21. The pathogenesis and basis for treatment in multiple sclerosis.
Compston A
Clin Neurol Neurosurg; 2004 Jun; 106(3):246-8. PubMed ID: 15177777
[TBL] [Abstract][Full Text] [Related]
22. Gray matter involvement in multiple sclerosis.
Pirko I; Lucchinetti CF; Sriram S; Bakshi R
Neurology; 2007 Feb; 68(9):634-42. PubMed ID: 17325269
[TBL] [Abstract][Full Text] [Related]
23. The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting.
Correale J; Villa A
Autoimmunity; 2007 Mar; 40(2):148-60. PubMed ID: 17453713
[TBL] [Abstract][Full Text] [Related]
24. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter.
Vercellino M; Masera S; Lorenzatti M; Condello C; Merola A; Mattioda A; Tribolo A; Capello E; Mancardi GL; Mutani R; Giordana MT; Cavalla P
J Neuropathol Exp Neurol; 2009 May; 68(5):489-502. PubMed ID: 19525897
[TBL] [Abstract][Full Text] [Related]
25. Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis.
Imitola J; Snyder EY; Khoury SJ
Physiol Genomics; 2003 Aug; 14(3):171-97. PubMed ID: 12923300
[TBL] [Abstract][Full Text] [Related]
26. Remyelination protects axons from demyelination-associated axon degeneration.
Irvine KA; Blakemore WF
Brain; 2008 Jun; 131(Pt 6):1464-77. PubMed ID: 18490361
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance techniques to quantify tissue damage, tissue repair, and functional cortical reorganization in multiple sclerosis.
Filippi M; Agosta F
Prog Brain Res; 2009; 175():465-82. PubMed ID: 19660674
[TBL] [Abstract][Full Text] [Related]
28. Protecting axons in multiple sclerosis.
Wilkins A; Scolding N
Mult Scler; 2008 Sep; 14(8):1013-25. PubMed ID: 18632772
[TBL] [Abstract][Full Text] [Related]
29. Neurodegeneration in multiple sclerosis: defining the problem.
Lisak RP
Neurology; 2007 May; 68(22 Suppl 3):S5-12; discussion S43-54. PubMed ID: 17548569
[TBL] [Abstract][Full Text] [Related]
30. Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system.
Vickers JC; King AE; Woodhouse A; Kirkcaldie MT; Staal JA; McCormack GH; Blizzard CA; Musgrove RE; Mitew S; Liu Y; Chuckowree JA; Bibari O; Dickson TC
Brain Res Bull; 2009 Oct; 80(4-5):217-23. PubMed ID: 19683034
[TBL] [Abstract][Full Text] [Related]
31. The pathology of multiple sclerosis.
Lucchinetti CF; Parisi J; Bruck W
Neurol Clin; 2005 Feb; 23(1):77-105, vi. PubMed ID: 15661089
[No Abstract] [Full Text] [Related]
32. Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance.
De Keyser J; Steen C; Mostert JP; Koch MW
J Cereb Blood Flow Metab; 2008 Oct; 28(10):1645-51. PubMed ID: 18594554
[TBL] [Abstract][Full Text] [Related]
33. [Regenerative capacity in multiple sclerosis].
Lubetzki C
Bull Acad Natl Med; 2008 Mar; 192(3):495-504; discussion 505-6. PubMed ID: 18819695
[TBL] [Abstract][Full Text] [Related]
34. [Neuronal injury in multiple sclerosis].
Correale J; Meli F; Ysrraelit C
Medicina (B Aires); 2006; 66(5):472-85. PubMed ID: 17137182
[TBL] [Abstract][Full Text] [Related]
35. Knowns and unknowns in the future of multiple sclerosis treatment.
Stüve O
J Neurol Sci; 2009 Dec; 287 Suppl 1():S30-6. PubMed ID: 20106346
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of axon-glial injury of the optic nerve.
Compston A
Eye (Lond); 2004 Nov; 18(11):1182-7. PubMed ID: 15534604
[TBL] [Abstract][Full Text] [Related]
37. Pathology and disease mechanisms in different stages of multiple sclerosis.
Lassmann H
J Neurol Sci; 2013 Oct; 333(1-2):1-4. PubMed ID: 23735777
[TBL] [Abstract][Full Text] [Related]
38. Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis.
Seewann A; Vrenken H; van der Valk P; Blezer EL; Knol DL; Castelijns JA; Polman CH; Pouwels PJ; Barkhof F; Geurts JJ
Arch Neurol; 2009 May; 66(5):601-9. PubMed ID: 19433660
[TBL] [Abstract][Full Text] [Related]
39. [Pathophysiology of multiple sclerosis].
Smith KJ
Rev Prat; 2006 Jun; 56(12):1299-303. PubMed ID: 16948217
[TBL] [Abstract][Full Text] [Related]
40. Future options for therapies to limit damage and enhance recovery.
Compston A
Semin Neurol; 1998; 18(3):405-14. PubMed ID: 9817543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
